The stock of NRx Pharmaceuticals Inc. (NASDAQ:NRXP) increased by $0.03 on Tuesday to finish at $0.33, up 12.36 percent. The last five days have seen an average of 7,650,120 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.7774. The average number of shares traded over the last 20 days was 2,311,460, while the average volume over the last 50 days totaled 1,121,094.
NRXP stock dropped -14.74% since last month. On 08/23/23, the company’s shares reached a one-month low of $0.2726. The stock touched a high of $1.54 on 01/13/23, after rallying from a low of $0.27 in 52 weeks. The price of NRXP stock has declined by -70.04% or -$0.7774 this year, reaching a new high 4 times. Still, the stock price is down -78.40% from the 52-week high.
Insider Transactions
NRXP stock investors should be aware that NRx Pharmaceuticals Inc. (NRXP) stock had its last reported insider trading activity 7 days ago on Aug 23. On Aug 23, Chief Scientist Javitt Jonathan C acquired 100,000 shares at $0.33 each. This transaction resulted in the insider spending $33,000. On Aug 22, Javitt Jonathan C added 200,000 shares at a price of US$0.32. After the transaction, the insider now owns 346,332 shares. CHIEF EXECUTIVE OFFICER Willard Stephen H had earlier bought 50,000 shares on Dec 16 for $1.17 a share. The transaction was completed for $58,500.
Financial Health
For the three months ended June 29, NRx Pharmaceuticals Inc.’s quick ratio was 0.90, while its current ratio was 0.90, indicating its inability to pay off its debt.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NRXP’s return on assets (ROA) during the last 12 months has been -169.50%. In the meantime, the return on equity (ROE) for the last 12 months was -740.90%.
Earnings Surprise
According to NRx Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. It was predicted that NRx Pharmaceuticals Inc.’s quarterly earnings would be -$0.12, but it ended up being -$0.14, beating the consensus by 14.30%. At the end of NRx Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 22.62 million, while its total debt was $12.69 million. Equity owned by shareholders amounts to $81.7 million.
Technical Picture
Here’s a quick look at NRx Pharmaceuticals Inc.’s (NRXP) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 51.24%, suggesting the stock is Neutral, with a 134.83% historical volatility rate.
The stochastic %K and %D were 47.15% and 44.98% respectively, while the average true range (ATR) was 0.0440. Based on the 14-day stochastic reading of 64.94%, the RSI (14) reading is 47.05%. On the 9-day MACD Oscillator, the stock is at -0.0007.
Analyst Ratings
Analysts have assigned NRx Pharmaceuticals Inc. (NRXP) an Buy rating. NRXP is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is NRXP’s price target for the next 12 months?
The current consensus forecast for the stock is between $2.00 and $9.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for NRx Pharmaceuticals Inc. (NRXP) is $5.33.
